Compare CBU & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBU | ICUI |
|---|---|---|
| Founded | 1866 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 1994 | 1995 |
| Metric | CBU | ICUI |
|---|---|---|
| Price | $64.91 | $183.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $66.67 | ★ $169.00 |
| AVG Volume (30 Days) | 257.3K | ★ 316.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | 15.41 | ★ 100.62 |
| EPS | ★ 2.24 | 1.96 |
| Revenue | $818,007,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $7.75 | $4.46 |
| P/E Ratio | ★ $28.59 | $92.51 |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $53.46 | $110.51 |
| 52 Week High | $71.11 | $192.85 |
| Indicator | CBU | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 44.32 | 70.63 |
| Support Level | $60.90 | $136.56 |
| Resistance Level | $64.83 | N/A |
| Average True Range (ATR) | 1.58 | 5.30 |
| MACD | -0.28 | 1.34 |
| Stochastic Oscillator | 37.84 | 75.16 |
Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional, and governmental customers. The Company also offers comprehensive financial planning, trust administration, and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services, and Wealth Management Services. The group generates the majority of its revenue from the Banking and Corporate segment.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.